Newsroom | 49719 results

YARDLEY, Pa.--(BUSINESS WIRE)--Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes research (HEOR) consultancy. The acquisition represents a key step in Red Nucleus’s strategy, strengthening its ability to help biopharmaceutical companies demonstrate the clinical and economic val...

SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs. Building on early success in Praxis’s innovative Essential3 Program for Essential Tremor, SEQ...

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel prophylactic Medical Countermeasures for warfighters, first responders, and others at risk of radiation exposure from nuclear incidents, industrial accidents, or cancer radiation therapy, today announced that RADM Colin G. Chinn, MC, USN (Ret), MD, the Company’s Chief Medical Officer, will be presenting at the Big Idea CONNECTpreneur Baltimore Forum on February 05,...

ORLANDO, Fla.--(BUSINESS WIRE)--Massive Bio today announced the launch of TrialRelay™, a physician-facing enrollment orchestration platform designed to eliminate one of oncology’s most persistent failures: patients getting lost after a clinical trial referral. The announcement will be made during the SCOPE Conference 2026, the leading global forum for clinical operations and innovation. For years, Massive Bio’s physician platform operated under the name Clinical Network. While accurate, the ter...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Gen Cytotoxic Therapeutic Leveraging the ELANE Pathway into the Clinic...

PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The Food and D...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI, a leading oncology real-world evidence and AI SaaS technology company, today unveiled Accelerated Clinical Trials (ACT), an enterprise agentic artificial intelligence (AI) platform designed to automate and inject predictive intelligence across the end-to-end clinical trial process. Launched at Summit for Clinical Ops Executives (SCOPE) 2026 in Orlando, ACT integrates real-world and proprietary data with advanced AI workflows to help sponsors and con...

WALTHAM, Mass. & SHANGHAI--(BUSINESS WIRE)--Ensem doses first patient in China in ETX-636 global Phase 1/2 study in cancer patients with activating PI3Kα mutations, including breast cancer...

美国马萨诸塞州WALTHAM及中国上海--(BUSINESS WIRE)--(美国商业资讯)-- 昂胜医药 (Ensem Therapeutics, Inc. 简称 ENSEM, 昂胜), 一家处于临床阶段、专注于肿瘤领域的创新型生物制药公司，今日宣布其在研创新药物 ETX-636 的全球 I/II 期临床研究已在上海复旦大学附属肿瘤医院完成中国首例患者给药。这一进展标志着该项目在中国正式进入临床阶段，也体现了公司全球研发与临床开发战略的持续推进。 ETX-636 是一款潜在的同类首创（first-in-class）及同类最佳（best-in-class）的变构型泛突变选择性 PI3Kα 双重抑制剂与降解剂。该药物正用于评估其在携带 PI3Kα 激活突变（包括乳腺癌）的肿瘤患者中的治疗潜力。ETX-636 在中国的快速临床启动，紧随其 2025 年 11 月 19 日 获得中国国家药品监督管理局（NMPA）临床试验申请（IND）批准之后。 昂胜医药联合创始人兼首席执行官 金圣芳博士 表示：“昂胜始终致力于为全球患者开发创新的精准肿瘤治疗方案。ETX-636 临床研究成功拓展至中国，是公...